Galapagos' Latest Advance: Its Licensing Deal with Janssen
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 90 (Table of Contents)
Published: 1 Dec-2007
DOI: 10.3833/pdr.v2007.i90.245 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
On the back of the successful building of its service division, BioFocus DPI, Galapagos has licensed its rheumatoid arthritis programme to Janssen Pharmaceutica (of Johnson and Johnson) in highly lucrative deal that could earn the company in excess of US$1 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS